Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  title={Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy},
  author={Roman Rouzier and Charles M. Perou and William Fraser Symmans and Nuhad K. Ibrahim and Massimo Cristofanilli and Keith Anderson and Kenneth R. Hess and James Stec and Mark Ayers and Peter Wagner and Paolo Morandi and Chang Fan and Islam Rabiul and Jeffrey S. Ross and Gabriel N. Hortobagyi and Lajos Pusztai},
  journal={Clinical Cancer Research},
  pages={5678 - 5685}
Purpose: Molecular classification of breast cancer has been proposed based on gene expression profiles of human tumors. Luminal, basal-like, normal-like, and erbB2+ subgroups were identified and were shown to have different prognoses. The goal of this research was to determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy. Experimental Design: Fine needle aspirations of 82 breast cancers were obtained before starting preoperative… 

Figures and Tables from this paper

Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer.

  • D. ZahaE. LazărC. Lăzureanu
  • Medicine, Biology
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • 2010
Molecular differences between previously known as well as newly defined subtypes of breast cancer have been shown to correlate very well with clinical features and survival, or even better than traditional histopathological parameters.

Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer

The progress in molecular subtyping of TNBC is discussed, providing a brief insight in novel TNBC biomarkers and therapeutic strategies, in order to develop a treatment specialized for each group of patients.

Basal Breast Cancer: A Complex and Deadly Molecular Subtype

The basal subtype, which represents 15-25% of cases, is characterized by an expression profile similar to that of myoepithelial normal mammary cells, and displays epidemiological and clinico-pathological features distinct from other subtypes.

Clinical and pathologic aspects of basal-like breast cancers

This Review appraises the current state of knowledge on the clinical and pathologic features of breast cancers classified as 'basal-like' by gene-expression profiling and/or immunohistochemical criteria.

Molecular subtypes in advanced breast cancer respond differently to neoadjuvant chemotherapy : assessment of complete pathologic response and prognosis

The study confirms that pCR was the favorable prognostic factor in OS in three molecular subtypes in patients with locally advanced breast cancer after receiving neoadjuvant chemotherapy with epirubicin and sequential docetaxel and indicates that the molecular mechanisms of susceptibility to NC vary between these two groups.

Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features.

The clinical background, the histologic profile, and the immunohistochemical profile of these tumors are provided and the current knowledge of their molecular signature and their implications on targeted molecular therapy are discussed.

Gene expression profiling: changing face of breast cancer classification and management.

Categorization of breast cancers by gene expression is only beginning to make its way into the daily clinical practice and likely will complement, but not replace, the conventional methods of classification.

From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change?

The main characteristics of the Molecular subclasses, the relationships with the conventional pathologic classification, critical problems of the molecular classification and their impact on prognosis and therapy are presented.

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

The clinical relevancy of the 7-subtype classification of triple-negative breast cancer reported by Lehmann and colleagues is confirmed, and may spur innovative personalized medicine strategies for patients with TNBC.



Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  • C. SotiriouS. Neo E. Liu
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
Gene expression patterns were found to be strongly associated with estrogen receptor (ER) status and moderately associated with grade, but not associated with menopausal status, nodal status, or tumor size, in an unselected group of 99 node-negative and node-positive breast cancer patients.

Repeated observation of breast tumor subtypes in independent gene expression data sets

The results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities.

Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer.

  • L. GianniM. Zambetti S. Shak
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
RT-PCR analysis of an ER gene cluster predicts pCR to primary chemotherapy, and addition of other genes increases predictive power, and Multivariate analysis indicates that combinations of genes are more powerful predictors of response than single genes.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

  • L. GianniM. Zambetti S. Shak
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Quantitative expression of ER-related genes, proliferation genes, and immune- related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel, suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate.

Molecular portraits of human breast tumours

Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.

  • R. RouzierJ. Extra E. Bourstyn
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
It is suggested that axillary status is a better prognostic factor than response of the primary tumor to primary chemotherapy in breast cancer patients treated with primary chemotherapy.